FDA Clears Updated COVID Vaccines for High-Risk Groups Amid Rising Cases

Key points

• FDA approved updated mRNA vaccines from Pfizer-BioNTech and Moderna, as well as a protein-based vaccine from Sanofi (formerly Novavax), for the 2026-2027 season.
• Approval is limited to adults aged 65 and older, and those aged 5-64 (Pfizer), 6 months-64 (Moderna Spikevax), or 12-64 (Moderna mNexspike and Sanofi) with at least one underlying health condition.
• The vaccines target the XFG subvariant of the JN.1 strain, which is currently predominant in the US, though some formulations also target the LP.8.1 strain.
• Vaccines are expected to begin shipping to pharmacies and clinics within days, with CVS confirming availability in all states as permitted by law.
• The CDC has not issued a formal federal recommendation for the general population due to legal limbo surrounding the Advisory Committee on Immunization Practices, but major medical societies recommend vaccination for high-risk groups.

Background

This approval follows a shift in federal policy from universal recommendations to a risk-based approach. Previous coverage noted that while COVID-19 activity is currently low, it is rising in 47 states, with the South and West expected to see stronger increases as fall approaches. Insurers have broadly pledged to cover the vaccines despite the lack of a formal federal recommendation, and states have worked to preserve pharmacy access through updated regulations.

How outlets are covering it

The Washington Post emphasizes the logistical challenges of distribution and the legal uncertainty surrounding federal recommendations, noting that while pharmacies are preparing, some states may require prescriptions for those outside the approved high-risk groups. CNN highlights the specific variants targeted by each manufacturer, noting that Pfizer targets LP.8.1 while Moderna and Sanofi target XFG and JN.1, respectively. UPI focuses on the immediate availability of the Pfizer-BioNTech vaccine, describing it as having a favorable safety profile and noting that COVID-19 is now viewed as a common respiratory ailment rather than an emergency. All sources agree that while case numbers are rising, they remain low compared to previous years, and that uptake remains low despite medical society recommendations.

Why it matters

The approval ensures that high-risk populations have access to updated protection against the current dominant variant, potentially mitigating severe illness and hospitalizations. The lack of a universal federal recommendation creates a fragmented landscape where access and coverage depend on state laws and individual provider decisions, highlighting the ongoing tension between public health guidance and political influence on vaccine policy.

What to watch

Vaccines are expected to be widely available in pharmacies and clinics within the coming days. Major medical societies are planning to release their specific recommendations in early September. The CDC is expected to eventually issue a formal recommendation, though the timeline is uncertain due to the legal status of the vaccine advisory panel. Patients should consult their healthcare providers to determine eligibility and access.